Update on Clinical Trial

Portal Forums Member Updates Lung Cancer Member Updates Update on Clinical Trial

This topic contains 63 replies, has 9 voices, and was last updated by catdander forum moderator catdander forum moderator 1 week ago.

Viewing 4 posts - 61 through 64 (of 64 total)
Author Posts   
Author Posts
January 4, 2017 at 11:46 am  #1289705    
catdander forum moderator
catdander forum moderator

Scohn,

Her cure leze? I like the sound of it. I can’t tell you how much we appreciate you sharing the incites into which decisions are made for treatment.

(((hugs and hope all around)))
Janine

January 4, 2017 at 1:41 pm  #1289709    

scohn

Thanks Janine. Cyber Hugs are welcome anytime! I hope you have the happiest of New Years, and I’ll keep in touch once we know more from this latest CT.


Wife, lifelong non-smoker, dx 4/24/15 adenocarcinoma, right middle lung, stage IV, poorly differentiated. 2 bone mets, 1 lymph node. HER2 Exon 20 mutation. 6x Carbo/Alimta – 50-70% reduction in primary tumor, lymph nodes normal, bone regrowth into lesion site. Alimta maintenance, not effective, tumor growth, 2 new liver mets. 11/15 – Opdivo; Not effective – tumor growth & new liver mets. 4/16 – clinical trial drug, tumor & liver met reduced 50-70%. 11/16-main tumor growth, liver mets stable.

  • This reply was modified 2 weeks ago by  scohn.
  • This reply was modified 2 weeks ago by  scohn.
January 11, 2017 at 8:54 am  #1289760    

scohn

Hi everyone.

So it looks like relatively good news from the latest CT scan, and POSSIBLA is holding up to the name we gave it. The main lung tumor still grew, but at a much slower rate than from the last CT scan. The one liver lesion that still lit up with last month’s PET scan also shrunk a little, after growing a little on the last CT scan – the other measured liver lesion that showed no PET activity last month stayed stable. No new metastases, no significant change in bone lesions, and a very minor increase in one lymph node in the area.

So it looks like everything is relatively stable this time, with reduced growth in the main tumor, and most importantly, no new metastases. This all seems to correspond with the experimental rationale for the drug that shows PTK7 is likely not just a marker for adenocarcinomas, but may be important in the ability of tumors to form new tumor initiating cells that support tumor growth and metastases.

So, we can take a bit of a breath now in seeing the regrowth we saw in the last CT scan has been tamped down a bit. My wife sees the oncologist for details (and her next POSSIBLA infusion) this afternoon, but for the moment it looks like my wife will stay on POSSIBLA, at least until the new ARIAD EGFR/HER2 TKI trial comes to Chicago in March or April.

Deep breaths, and one day, one CT scan at a time. Another emotional Gatorade® for the marathon.

As always – my heart and hugs go out to all those going through this. A chorus that my wife and I are in is singing at a memorial service this weekend for a member who died recently of cancer, which keeps the scourge even more on my mind.


Wife, lifelong non-smoker, dx 4/24/15 adenocarcinoma, right middle lung, stage IV, poorly differentiated. 2 bone mets, 1 lymph node. HER2 Exon 20 mutation. 6x Carbo/Alimta – 50-70% reduction in primary tumor, lymph nodes normal, bone regrowth into lesion site. Alimta maintenance, not effective, tumor growth, 2 new liver mets. 11/15 – Opdivo; Not effective – tumor growth & new liver mets. 4/16 – clinical trial drug, tumor & liver met reduced 50-70%. 11/16-main tumor growth, liver mets stable.

January 11, 2017 at 10:07 am  #1289765    
catdander forum moderator
catdander forum moderator

!!!YaY!!! So good to hear the news. Anything’s POSSIBLA…
I am sorry about your friend and fellow caroler. It makes it even more difficult to see when you are going through the cancer experience yourself.

Take care you two.
Janine

Viewing 4 posts - 61 through 64 (of 64 total)

You must be logged in to reply to this topic.